Overall, individuals with migraine-like pain reported the most frequent pain improvement (73.2%), generally with a combination of oral (α2δ ligands) and adjuvant (TNS) therapies, while the postsurgical group had the lowest overall response rate (40.7%) to the various therapies. Here, ATXN2L is linked to migraine disorder.